Dalcetrapib (BioDeep_00000177935)

   

human metabolite blood metabolite


代谢物信息卡片


1-(2-Ethylbutyl)-N-{2-[(2-methylpropanoyl)sulphanyl]phenyl}cyclohexane-1-carboximidic acid

化学式: C23H35NO2S (389.23883700000005)
中文名称: CETP抑制剂
谱图信息: 最多检出来源 Homo sapiens(blood) 7.14%

分子结构信息

SMILES: CC(C)C(SC1=C(NC(C2(CC(CC)CC)CCCCC2)=O)C=CC=C1)=O
InChI: InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)

描述信息

D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D009676 - Noxae > D000963 - Antimetabolites
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively[1][2].

同义名列表

9 个代谢物同义名

1-(2-Ethylbutyl)-N-{2-[(2-methylpropanoyl)sulphanyl]phenyl}cyclohexane-1-carboximidic acid; 1-(2-Ethylbutyl)-N-{2-[(2-methylpropanoyl)sulphanyl]phenyl}cyclohexane-1-carboximidate; 1-(2-Ethylbutyl)-N-{2-[(2-methylpropanoyl)sulfanyl]phenyl}cyclohexane-1-carboximidate; 1-(2-ethylbutyl)-N-{2-[(2-methylpropanoyl)sulfanyl]phenyl}cyclohexane-1-carboxamide; Dalcetrapib; RO4607381; R04607381; JTT-705; JTT 705



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mathieu R Brodeur, David Rhainds, Daniel Charpentier, Marie Boulé, Téodora Mihalache-Avram, Mélanie Mecteau, Geneviève Brand, Valérie Pedneault-Gagnon, Annik Fortier, Eric J Niesor, Eric Rhéaume, Cyrille Maugeais, Jean-Claude Tardif. Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans. Journal of lipid research. 2023 01; 64(1):100316. doi: 10.1016/j.jlr.2022.100316. [PMID: 36410424]
  • Azita H Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand, Hamid Ariannejad, Aakriti Gupta, Mahesh V Madhavan, Benjamin W Van Tassell, David Jimenez, Manuel Monreal, Muthiah Vaduganathan, John Fanikos, Dave L Dixon, Gregory Piazza, Sahil A Parikh, Deepak L Bhatt, Gregory Y H Lip, Gregg W Stone, Harlan M Krumholz, Peter Libby, Samuel Z Goldhaber, Behnood Bikdeli. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2021 10; 78(16):1635-1654. doi: 10.1016/j.jacc.2021.08.021. [PMID: 34649702]
  • Amand F Schmidt, Nicholas B Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Mika Kivimaki, Deborah A Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C Bis, Christopher J O'Donnell, Goya Wannamethee, Andrew Wong, Jackie F Price, Alun D Hughes, Tom R Gaunt, Nora Franceschini, Dennis O Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D Hingorani, Chris Finan. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature communications. 2021 09; 12(1):5640. doi: 10.1038/s41467-021-25703-3. [PMID: 34561430]
  • Mateja Manček-Keber, Iva Hafner-Bratkovič, Duško Lainšček, Mojca Benčina, Tea Govednik, Sara Orehek, Tjaša Plaper, Vid Jazbec, Valter Bergant, Vincent Grass, Andreas Pichlmair, Roman Jerala. Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2021 06; 35(6):e21651. doi: 10.1096/fj.202100560r. [PMID: 34004056]
  • David Rhainds, Chris J Packard, Mathieu R Brodeur, Eric J Niesor, Frank M Sacks, J Wouter Jukema, R Scott Wright, David D Waters, Therese Heinonen, Donald M Black, Fouzia Laghrissi-Thode, Marie-Pierre Dubé, Marc A Pfeffer, Jean-Claude Tardif. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine. Circulation. Genomic and precision medicine. 2021 04; 14(2):e003219. doi: 10.1161/circgen.121.003219. [PMID: 33794646]
  • Hiroaki Takubo, Tomohiro Ishikawa, Toshio Taniguchi, Kazunori Iwanaga, Yukihiro Nomura. The influence of multiple oral administration on the pharmacokinetics and distribution profile of dalcetrapib in rats. Xenobiotica; the fate of foreign compounds in biological systems. 2021 Jan; 51(1):82-87. doi: 10.1080/00498254.2020.1809030. [PMID: 32783571]
  • Hiroaki Takubo, Toshio Taniguchi, Kazunori Iwanaga, Yukihiro Nomura. Evaluation of the changes in exposure to thiol compounds in chronic kidney disease patients using the PBPK model. Xenobiotica; the fate of foreign compounds in biological systems. 2021 Jan; 51(1):31-39. doi: 10.1080/00498254.2020.1805816. [PMID: 32744915]
  • Gregory G Schwartz, Lawrence A Leiter, Christie M Ballantyne, Philip J Barter, Donald M Black, David Kallend, Fouzia Laghrissi-Thode, Eran Leitersdorf, John J V McMurray, Stephen J Nicholls, Anders G Olsson, David Preiss, Prediman K Shah, Jean-Claude Tardif, John Kittelson. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes care. 2020 05; 43(5):1077-1084. doi: 10.2337/dc19-2204. [PMID: 32144166]
  • Christophe Husser, Axel Pähler, Mark Seymour, Olaf Kuhlmann, Simone Schadt, Manfred Zell. Profiling of dalcetrapib metabolites in human plasma by accelerator mass spectrometry and investigation of the free phenothiol by derivatisation with methylacrylate. Journal of pharmaceutical and biomedical analysis. 2018 Apr; 152(?):143-154. doi: 10.1016/j.jpba.2018.01.022. [PMID: 29414006]
  • Ken Yamada, Margaret Brousseau, Wataru Honma, Akiko Iimura, Hidetomo Imase, Yuki Iwaki, Toshio Kawanami, Daniel LaSala, Guiqing Liang, Hironobu Mitani, Kazuhiko Nonomura, Osamu Ohmori, Meihui Pan, Dean F Rigel, Ichiro Umemura, Kayo Yasoshima, Guoming Zhu, Muneto Mogi. Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma. Journal of medicinal chemistry. 2017 10; 60(20):8466-8481. doi: 10.1021/acs.jmedchem.7b00900. [PMID: 29035537]
  • Dongyin Chen, Xin Huang, Hongwen Zhou, Hanqiong Luo, Pengfei Wang, Yongzhi Chang, Xinyi He, Suiying Ni, Qingqing Shen, Guoshen Cao, Hongbin Sun, Xiaoan Wen, Jun Liu. Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors. European journal of medicinal chemistry. 2017 Oct; 139(?):201-213. doi: 10.1016/j.ejmech.2017.08.012. [PMID: 28802120]
  • Theodosios D Filippatos, Anastazia Kei, Moses S Elisaf. Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. Diseases (Basel, Switzerland). 2017 Sep; 5(4):. doi: 10.3390/diseases5040021. [PMID: 28961179]
  • Mathieu R Brodeur, David Rhainds, Daniel Charpentier, Teodora Mihalache-Avram, Mélanie Mecteau, Geneviève Brand, Evelyne Chaput, Anne Perez, Eric J Niesor, Eric Rhéaume, Cyrille Maugeais, Jean-Claude Tardif. Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys. Journal of lipid research. 2017 07; 58(7):1282-1291. doi: 10.1194/jlr.m068940. [PMID: 28515138]
  • Spencer Phillips Hey, Jessica M Franklin, Jerry Avorn, Aaron S Kesselheim. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors. Circulation. Cardiovascular quality and outcomes. 2017 Jun; 10(6):. doi: 10.1161/circoutcomes.116.003121. [PMID: 28611186]
  • Jean-Claude Tardif, David Rhainds, Eric Rhéaume, Marie-Pierre Dubé. CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib. Arteriosclerosis, thrombosis, and vascular biology. 2017 Mar; 37(3):396-400. doi: 10.1161/atvbaha.116.307122. [PMID: 28126828]
  • T D Filippatos, E Klouras, F Barkas, M Elisaf. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert review of cardiovascular therapy. 2016 Aug; 14(8):953-62. doi: 10.1080/14779072.2016.1189327. [PMID: 27171534]
  • Eder C R Quintão. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?. European journal of clinical investigation. 2016 Jun; 46(6):581-9. doi: 10.1111/eci.12626. [PMID: 26992444]
  • Philip J Barter, Stephen J Nicholls, John J P Kastelein, Kerry-Anne Rye. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case. Circulation. 2015 Aug; 132(5):423-32. doi: 10.1161/circulationaha.114.014025. [PMID: 26240263]
  • G Kees Hovingh, Kausik K Ray, S Matthijs Boekholdt. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?. Circulation. 2015 Aug; 132(5):433-40. doi: 10.1161/circulationaha.115.014026. [PMID: 26240264]
  • G Kees Hovingh, John J P Kastelein, Sander J H van Deventer, Patrick Round, John Ford, Danish Saleheen, Daniel J Rader, H Bryan Brewer, Philip J Barter. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet (London, England). 2015 Aug; 386(9992):452-60. doi: 10.1016/s0140-6736(15)60158-1. [PMID: 26047975]
  • Francisco J Rios, Karla B Neves, Aurelie Nguyen Dinh Cat, Sarah Even, Roberto Palacios, Augusto C Montezano, Rhian M Touyz. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes. The Journal of pharmacology and experimental therapeutics. 2015 Apr; 353(1):27-34. doi: 10.1124/jpet.114.221002. [PMID: 25617244]
  • Eric J Niesor, David Kallend, Darren Bentley, John J P Kastelein, G Kees Hovingh, Erik S G Stroes. Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations. Lipids. 2014 Dec; 49(12):1245-9. doi: 10.1007/s11745-014-3956-x. [PMID: 25281277]
  • Eric J Niesor, Evelyne Chaput, Jean-Luc Mary, Andreas Staempfli, Andreas Topp, Andrea Stauffer, Haiyan Wang, Alexandre Durrwell. Effect of compounds affecting ABCA1 expression and CETP activity on the HDL pathway involved in intestinal absorption of lutein and zeaxanthin. Lipids. 2014 Dec; 49(12):1233-43. doi: 10.1007/s11745-014-3958-8. [PMID: 25300953]
  • Hiroaki Takubo, Tomohiro Ishikawa, Olaf Kuhlmann, Hiroyuki Nemoto, Tomoyuki Noguchi, Toyomichi Nanayama, Hiroshi Komura, Motohiro Kogayu. Pharmacokinetics and disposition of dalcetrapib in rats and monkeys. Xenobiotica; the fate of foreign compounds in biological systems. 2014 Dec; 44(12):1117-26. doi: 10.3109/00498254.2014.932471. [PMID: 24954481]
  • François Briand, Quentin Thieblemont, Elodie Muzotte, Noémie Burr, Isabelle Urbain, Thierry Sulpice, Douglas G Johns. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters. European journal of pharmacology. 2014 Oct; 740(?):135-43. doi: 10.1016/j.ejphar.2014.06.022. [PMID: 25008069]
  • Bin Dong, Amar Bahadur Singh, Chin Fung, Kelvin Kan, Jingwen Liu. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 2014 Aug; 235(2):449-62. doi: 10.1016/j.atherosclerosis.2014.05.931. [PMID: 24950000]
  • Kausik K Ray, Marc Ditmarsch, David Kallend, Eric J Niesor, Gabriela Suchankova, Ruchi Upmanyu, Judith Anzures-Cabrera, Valerie Lehnert, Meike Pauly-Evers, Ingar Holme, Josef Štásek, Maarten W J van Hessen, Peter Jones. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. European heart journal. 2014 Jul; 35(27):1792-800. doi: 10.1093/eurheartj/ehu105. [PMID: 24639426]
  • Daniel J Rader, Emil M deGoma. Future of cholesteryl ester transfer protein inhibitors. Annual review of medicine. 2014; 65(?):385-403. doi: 10.1146/annurev-med-050311-163305. [PMID: 24422575]
  • Hyun Joon Shin, Peter A McCullough. Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease. Nephron. Clinical practice. 2014; 127(1-4):158-64. doi: 10.1159/000363552. [PMID: 25343842]
  • Sheng-Ping Wang, Erin Daniels, Ying Chen, Jose Castro-Perez, Haihong Zhou, Karen O Akinsanya, Stephen F Previs, Thomas P Roddy, Douglas G Johns. In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption. Journal of lipid research. 2013 Oct; 54(10):2858-65. doi: 10.1194/jlr.m041541. [PMID: 23898048]
  • Raphaël Duivenvoorden, Venkatesh Mani, Mark Woodward, David Kallend, Gabriela Suchankova, Valentin Fuster, James H F Rudd, Ahmed Tawakol, Michael E Farkouh, Zahi A Fayad. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. JACC. Cardiovascular imaging. 2013 Oct; 6(10):1087-1094. doi: 10.1016/j.jcmg.2013.03.009. [PMID: 24135322]
  • Amir Hooshang Mohammadpour, Fatemeh Akhlaghi. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clinical pharmacokinetics. 2013 Aug; 52(8):615-26. doi: 10.1007/s40262-013-0071-8. [PMID: 23658137]
  • Andrew L Siebel, Alaina K Natoli, Felicia Y T Yap, Andrew L Carey, Medini Reddy-Luthmoodoo, Dmitri Sviridov, Chek Ing Kiu Weber, Georgina Meneses-Lorente, Cyrille Maugeais, Josephine M Forbes, Bronwyn A Kingwell. Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circulation research. 2013 Jul; 113(2):167-75. doi: 10.1161/circresaha.113.300689. [PMID: 23676183]
  • Jonathan D Schofield, Michael France, Basil Ammori, Yifen Liu, Handrean Soran. High-density lipoprotein cholesterol raising: does it matter?. Current opinion in cardiology. 2013 Jul; 28(4):464-74. doi: 10.1097/hco.0b013e328362210d. [PMID: 23736820]
  • Ernst J Schaefer. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?. Current opinion in lipidology. 2013 Jun; 24(3):259-64. doi: 10.1097/mol.0b013e3283612454. [PMID: 23652567]
  • Mary Phelan, Judith Anzures-Cabrera, David J Carlile, Lucy Rowell, Olaf Kuhlmann, Gerhard Arold, Richard Robson, Darren Bentley. Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?. Clinical pharmacokinetics. 2013 Apr; 52(4):255-65. doi: 10.1007/s40262-013-0035-z. [PMID: 23400900]
  • Chuanwei Li, Wen Zhang, Faying Zhou, Caiyu Chen, Liang Zhou, Yafei Li, Ling Liu, Fang Pei, Hao Luo, Zhangxue Hu, Jing Cai, Chunyu Zeng. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. PloS one. 2013; 8(10):e77049. doi: 10.1371/journal.pone.0077049. [PMID: 24204732]
  • Gregory G Schwartz, Anders G Olsson, Markus Abt, Christie M Ballantyne, Philip J Barter, Jochen Brumm, Bernard R Chaitman, Ingar M Holme, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Hardi Mundl, Stephen J Nicholls, Prediman K Shah, Jean-Claude Tardif, R Scott Wright. Effects of dalcetrapib in patients with a recent acute coronary syndrome. The New England journal of medicine. 2012 Nov; 367(22):2089-99. doi: 10.1056/nejmoa1206797. [PMID: 23126252]
  • Mariarita Puntoni, Francesco Sbrana, Federico Bigazzi, Tiziana Sampietro. Tangier disease: epidemiology, pathophysiology, and management. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2012 Oct; 12(5):303-11. doi: 10.2165/11634140-000000000-00000. [PMID: 22913675]
  • Philip J Barter, Kerry-Anne Rye. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of lipid research. 2012 Sep; 53(9):1755-66. doi: 10.1194/jlr.r024075. [PMID: 22550134]
  • Michael H Davidson. HDL and CETP Inhibition: Will This DEFINE the Future?. Current treatment options in cardiovascular medicine. 2012 Aug; 14(4):384-90. doi: 10.1007/s11936-012-0191-8. [PMID: 22723175]
  • Bernd Hewing, Edward A Fisher. Rationale for cholesteryl ester transfer protein inhibition. Current opinion in lipidology. 2012 Aug; 23(4):372-6. doi: 10.1097/mol.0b013e328353ef1d. [PMID: 22517614]
  • Katja Heinig, Franz Bucheli, Olaf Kuhlmann, Manfred Zell, Axel Pähler, Elke Zwanziger, Günter Gross, Joseph Tardio, Tomohiro Ishikawa, Tomoko Yamashita. Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2012 Jul; 66(?):314-24. doi: 10.1016/j.jpba.2012.03.056. [PMID: 22541249]
  • Eric J Niesor, Elisabeth von der Mark, Laura Calabresi, Maurizio Averna, Angelo B Cefalù, Patrizia Tarugi, Peter Nilsson, Gregor Dernick. Lipid and apoprotein composition of HDL in partial or complete CETP deficiency. Current vascular pharmacology. 2012 Jul; 10(4):422-31. doi: 10.2174/157016112800812683. [PMID: 22339301]
  • Maria-Carmen Fernandez, Ana Escribano, Ana I Mateo, Saravanan Parthasarathy, Eva M Martin de la Nava, Xiaodong Wang, Sandra L Cockerham, Thomas P Beyer, Robert J Schmidt, Guoqing Cao, Youyan Zhang, Timothy M Jones, Anthony Borel, Stephanie A Sweetana, Ellen A Cannady, Gregory Stephenson, Scott Frank, Nathan B Mantlo. Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors. Bioorganic & medicinal chemistry letters. 2012 May; 22(9):3056-62. doi: 10.1016/j.bmcl.2012.03.075. [PMID: 22497761]
  • Annie Young, Judith Anzures-Cabrera, Michael Derks. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30). International journal of clinical pharmacology and therapeutics. 2012 Apr; 50(4):248-56. doi: 10.5414/cp201647. [PMID: 22456295]
  • Wijtske Annema, Uwe Jf Tietge. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutrition & metabolism. 2012 Mar; 9(1):25. doi: 10.1186/1743-7075-9-25. [PMID: 22458435]
  • Douglas G Johns, Joseph Duffy, Timothy Fisher, Brian K Hubbard, Michael J Forrest. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs. 2012 Mar; 72(4):491-507. doi: 10.2165/11599310-000000000-00000. [PMID: 22356288]
  • Hisashi Shinkai. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vascular health and risk management. 2012; 8(?):323-31. doi: 10.2147/vhrm.s25238. [PMID: 22661899]
  • Artturi Koivuniemi, Timo Vuorela, Petri T Kovanen, Ilpo Vattulainen, Marja T Hyvönen. Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations. PLoS computational biology. 2012 Jan; 8(1):e1002299. doi: 10.1371/journal.pcbi.1002299. [PMID: 22253581]
  • Alyse S Goldberg, Robert A Hegele. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug design, development and therapy. 2012; 6(?):251-9. doi: 10.2147/dddt.s34976. [PMID: 23055695]
  • A F H Stalenhoef, M H Davidson, J G Robinson, T Burgess, R Duttlinger-Maddux, D Kallend, A C Goldberg, H Bays. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes, obesity & metabolism. 2012 Jan; 14(1):30-9. doi: 10.1111/j.1463-1326.2011.01485.x. [PMID: 21819519]
  • Klaus G Parhofer. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core evidence. 2012; 7(?):29-38. doi: 10.2147/ce.s25239. [PMID: 22701100]
  • Marcin Barylski, Jolanta Małyszko, Jacek Rysz, Michał Myśliwiec, Maciej Banach. Lipids, blood pressure, kidney - what was new in 2011?. Archives of medical science : AMS. 2011 Dec; 7(6):1055-66. doi: 10.5114/aoms.2011.26620. [PMID: 22328891]
  • Eric J Niesor, Evelyne Chaput, Andreas Staempfli, Denise Blum, Michael Derks, David Kallend. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis. 2011 Dec; 219(2):761-7. doi: 10.1016/j.atherosclerosis.2011.09.017. [PMID: 21982411]
  • Gregor Dernick, Stefan Obermüller, Cyrill Mangold, Christine Magg, Hugues Matile, Oliver Gutmann, Elisabeth von der Mark, Corinne Handschin, Cyrille Maugeais, Eric J Niesor. Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays. Journal of lipid research. 2011 Dec; 52(12):2323-2331. doi: 10.1194/jlr.d016824. [PMID: 21971713]
  • B Sjouke, D M Kusters, J J P Kastelein, G K Hovingh. Familial hypercholesterolemia: present and future management. Current cardiology reports. 2011 Dec; 13(6):527-36. doi: 10.1007/s11886-011-0219-9. [PMID: 21938413]
  • Philip Barter, Kerry-Anne Rye. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?. Trends in pharmacological sciences. 2011 Dec; 32(12):694-9. doi: 10.1016/j.tips.2011.07.004. [PMID: 22088767]
  • Paul J W H Kappelle, Arie van Tol, Bruce H R Wolffenbuttel, Robin P F Dullaart. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Cardiovascular therapeutics. 2011 Dec; 29(6):e89-99. doi: 10.1111/j.1755-5922.2010.00201.x. [PMID: 20645987]
  • Cesare R Sirtori. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention. Expert opinion on investigational drugs. 2011 Nov; 20(11):1543-54. doi: 10.1517/13543784.2011.614946. [PMID: 21961529]
  • Santiago Redondo, José Martínez-González, Concha Urraca, Teresa Tejerina. Emerging therapeutic strategies to enhance HDL function. Lipids in health and disease. 2011 Oct; 10(?):175. doi: 10.1186/1476-511x-10-175. [PMID: 21985435]
  • Eric J Niesor. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Current opinion in lipidology. 2011 Aug; 22(4):288-95. doi: 10.1097/mol.0b013e3283475e00. [PMID: 21587074]
  • Zahi A Fayad, Venkatesh Mani, Mark Woodward, David Kallend, Sameer Bansilal, Joseph Pozza, Tracy Burgess, Valentin Fuster, James H F Rudd, Ahmed Tawakol, Michael E Farkouh. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. American heart journal. 2011 Aug; 162(2):214-221.e2. doi: 10.1016/j.ahj.2011.05.006. [PMID: 21835280]
  • M John Chapman, Henry N Ginsberg, Pierre Amarenco, Felicita Andreotti, Jan Borén, Alberico L Catapano, Olivier S Descamps, Edward Fisher, Petri T Kovanen, Jan Albert Kuivenhoven, Philippe Lesnik, Luis Masana, Børge G Nordestgaard, Kausik K Ray, Zeljko Reiner, Marja-Riitta Taskinen, Lale Tokgözoglu, Anne Tybjærg-Hansen, Gerald F Watts. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European heart journal. 2011 Jun; 32(11):1345-61. doi: 10.1093/eurheartj/ehr112. [PMID: 21531743]
  • Antonio Arteaga, Attilio Rigotti. [Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act 'A rebirth of hope']. Revista medica de Chile. 2011 Jun; 139(6):802-6. doi: /s0034-98872011000600016. [PMID: 22051763]
  • Raphaël Duivenvoorden, Zahi A Fayad. Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies. Current atherosclerosis reports. 2011 Jun; 13(3):277-84. doi: 10.1007/s11883-011-0176-1. [PMID: 21465111]
  • Olaf Kuhlmann, Katja Heinig. Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey. Xenobiotica; the fate of foreign compounds in biological systems. 2011 May; 41(5):430-6. doi: 10.3109/00498254.2010.551223. [PMID: 21348578]
  • Michael Derks, Judith Anzures-Cabrera, Lynn Turnbull, Mary Phelan. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study. Clinical drug investigation. 2011; 31(5):325-35. doi: 10.1007/bf03256931. [PMID: 21366361]
  • Marta A Miyares. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. The Annals of pharmacotherapy. 2011 Jan; 45(1):84-94. doi: 10.1345/aph.1p446. [PMID: 21205945]
  • John J P Kastelein, Raphaël Duivenvoorden, John Deanfield, Eric de Groot, J Wouter Jukema, Juan-Carlos Kaski, Thomas Münzel, Stefano Taddei, Valerie Lehnert, Tracy Burgess, David Kallend, Thomas F Lüscher. Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Current medical research and opinion. 2011 Jan; 27(1):141-50. doi: 10.1185/03007995.2010.536207. [PMID: 21128879]
  • Richard Kones. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug design, development and therapy. 2011; 5(?):325-80. doi: 10.2147/dddt.s14934. [PMID: 21792295]
  • Eric J Niesor, Christine Magg, Naoto Ogawa, Hiroshi Okamoto, Elisabeth von der Mark, Hugues Matile, Georg Schmid, Roger G Clerc, Evelyne Chaput, Denise Blum-Kaelin, Walter Huber, Ralf Thoma, Philippe Pflieger, Makoto Kakutani, Daisuke Takahashi, Gregor Dernick, Cyrille Maugeais. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. Journal of lipid research. 2010 Dec; 51(12):3443-54. doi: 10.1194/jlr.m008706. [PMID: 20861162]
  • Michael Derks, Markus Abt, Mary Phelan. Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe. British journal of clinical pharmacology. 2010 Dec; 70(6):825-33. doi: 10.1111/j.1365-2125.2010.03763.x. [PMID: 21175438]
  • Michael Derks, Markus Abt, Graeme Parr, Georgina Meneses-Lorente, Anne-Marie Young, Mary Phelan. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Expert opinion on investigational drugs. 2010 Oct; 19(10):1135-45. doi: 10.1517/13543784.2010.509342. [PMID: 20738227]
  • Mollie Ranalletta, Kathleen K Bierilo, Ying Chen, Denise Milot, Qing Chen, Elaine Tung, Caroline Houde, Nadine H Elowe, Margarita Garcia-Calvo, Gene Porter, Suzanne Eveland, Betsy Frantz-Wattley, Mike Kavana, George Addona, Peter Sinclair, Carl Sparrow, Edward A O'Neill, Ken S Koblan, Ayesha Sitlani, Brian Hubbard, Timothy S Fisher. Biochemical characterization of cholesteryl ester transfer protein inhibitors. Journal of lipid research. 2010 Sep; 51(9):2739-52. doi: 10.1194/jlr.m007468. [PMID: 20458119]
  • Christos Paras, M Mahmood Hussain, Robert S Rosenson. Emerging drugs for hyperlipidemia. Expert opinion on emerging drugs. 2010 Sep; 15(3):433-51. doi: 10.1517/14728214.2010.481282. [PMID: 20423271]
  • Smita Negi, Christie M Ballantyne. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. Journal of clinical lipidology. 2010 Sep; 4(5):365-70. doi: 10.1016/j.jacl.2010.08.008. [PMID: 21122680]
  • Michael H Davidson. Update on CETP inhibition. Journal of clinical lipidology. 2010 Sep; 4(5):394-8. doi: 10.1016/j.jacl.2010.08.003. [PMID: 21122682]
  • Michael Derks, Markus Abt, Anne Mwangi, Georgina Meneses-Lorente. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. European journal of clinical pharmacology. 2010 Aug; 66(8):775-83. doi: 10.1007/s00228-010-0841-2. [PMID: 20521033]
  • Jennifer G Robinson. Dalcetrapib: a review of Phase II data. Expert opinion on investigational drugs. 2010 Jun; 19(6):795-805. doi: 10.1517/13543784.2010.488219. [PMID: 20465364]
  • Christian Besler, Kathrin Heinrich, Meliana Riwanto, Thomas F Lüscher, Ulf Landmesser. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Current pharmaceutical design. 2010 May; 16(13):1480-93. doi: 10.2174/138161210791051013. [PMID: 20196740]
  • Anne Perez, Matthew B Wright, Cyrille Maugeais, Annamaria Braendli-Baiocco, Hiroshi Okamoto, Akemi Takahashi, Thomas Singer, Lutz Mueller, Eric J Niesor. MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages. Toxicology in vitro : an international journal published in association with BIBRA. 2010 Apr; 24(3):745-50. doi: 10.1016/j.tiv.2010.01.002. [PMID: 20074633]
  • J Pöss, M Böhm, U Laufs. [HDL and CETP in atherogenesis]. Deutsche medizinische Wochenschrift (1946). 2010 Feb; 135(5):188-92. doi: 10.1055/s-0030-1247862. [PMID: 20082258]
  • Evan A Stein, Eli M Roth, James M Rhyne, Tracy Burgess, David Kallend, Jennifer G Robinson. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. European heart journal. 2010 Feb; 31(4):480-8. doi: 10.1093/eurheartj/ehp601. [PMID: 20097702]
  • M John Chapman, Wilfried Le Goff, Maryse Guerin, Anatol Kontush. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. European heart journal. 2010 Jan; 31(2):149-64. doi: 10.1093/eurheartj/ehp399. [PMID: 19825813]
  • Ján Murín, Miroslav Pernický, Soňa Kiňová. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?]. Vnitrni lekarstvi. Fall 201; 62(10):789-794. doi: NULL. [PMID: 27900865]
  • E S G Stroes, J J P Kastelein, A Bénardeau, O Kuhlmann, D Blum, L A Campos, R G Clerc, E J Niesor. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. British journal of pharmacology. 2009 Dec; 158(7):1763-70. doi: 10.1111/j.1476-5381.2009.00460.x. [PMID: 19917065]
  • Menno Vergeer, Erik S G Stroes. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. The American journal of cardiology. 2009 Nov; 104(10 Suppl):32E-8E. doi: 10.1016/j.amjcard.2009.09.017. [PMID: 19895942]
  • Laura K Potter, Dennis L Sprecher, Max C Walker, Frank L Tobin. Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro. Journal of lipid research. 2009 Nov; 50(11):2222-34. doi: 10.1194/jlr.m900015-jlr200. [PMID: 19282272]
  • Frank Hermann, Frank Enseleit, Lukas E Spieker, Daniel Périat, Isabella Sudano, Matthias Hermann, Roberto Corti, Georg Noll, Frank Ruschitzka, Thomas F Lüscher. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thrombosis research. 2009; 123(3):460-5. doi: 10.1016/j.thromres.2008.06.022. [PMID: 18789492]
  • Alexander J M Rennings, Anton F H Stalenhoef. JTT-705: is there still future for a CETP inhibitor after torcetrapib?. Expert opinion on investigational drugs. 2008 Oct; 17(10):1589-97. doi: 10.1517/13543784.17.10.1589. [PMID: 18808319]
  • Rakhi Shah Barkowski, William H Frishman. HDL metabolism and CETP inhibition. Cardiology in review. 2008 May; 16(3):154-62. doi: 10.1097/crd.0b013e31816a3b60. [PMID: 18414186]
  • Vasilios G Athyros, Anna Kakafika, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P Mikhailidis. Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert opinion on investigational drugs. 2008 Apr; 17(4):445-9. doi: 10.1517/13543784.17.4.445. [PMID: 18363511]
  • Kishor S Jain, M K Kathiravan, Rahul S Somani, Chamanlal J Shishoo. The biology and chemistry of hyperlipidemia. Bioorganic & medicinal chemistry. 2007 Jul; 15(14):4674-99. doi: 10.1016/j.bmc.2007.04.031. [PMID: 17521912]
  • Hiroshi Okamoto, Atsuko Miyai, Tomohiko Sasase, Noboru Furukawa, Mutsuyoshi Matsushita, Takamitsu Nakano, Katsuyuki Nakajima. Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma. Clinica chimica acta; international journal of clinical chemistry. 2007 Jan; 375(1-2):92-8. doi: 10.1016/j.cca.2006.06.015. [PMID: 16859664]
  • M John Chapman. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacology & therapeutics. 2006 Sep; 111(3):893-908. doi: 10.1016/j.pharmthera.2006.02.003. [PMID: 16574234]
  • Ernst J Schaefer, Bela F Asztalos. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Current opinion in lipidology. 2006 Aug; 17(4):394-8. doi: 10.1097/01.mol.0000236364.63840.d8. [PMID: 16832162]
  • W A Van der Steeg, K El-Harchaoui, J A Kuivenhoven, J J P Kastelein. Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?. Current drug targets. Cardiovascular & haematological disorders. 2005 Dec; 5(6):481-8. doi: 10.2174/156800605774961997. [PMID: 16503868]
  • C Daniel Meyers, Moti L Kashyap. Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Current opinion in cardiology. 2005 Jul; 20(4):307-12. doi: 10.1097/01.hco.0000167718.30076.24. [PMID: 15956828]